Castle Biosciences Files 8-K on Security Holder Rights & Corporate Actions

Ticker: CSTL · Form: 8-K · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, filing-update, shareholder-rights

TL;DR

Castle Biosciences filed an 8-K detailing changes to security holder rights and corporate governance matters.

AI Summary

On May 22, 2025, Castle Biosciences, Inc. filed an 8-K report detailing several key events. These include material modifications to the rights of security holders, amendments to its articles of incorporation or bylaws, and the submission of matters to a vote of security holders. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates significant corporate governance and potential changes affecting shareholder rights and company structure, requiring investor attention.

Risk Assessment

Risk Level: medium — The filing involves changes to security holder rights and corporate governance, which can introduce uncertainty and impact shareholder value.

Key Numbers

Key Players & Entities

FAQ

What specific modifications were made to the rights of security holders?

The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary text.

What were the key amendments to Castle Biosciences' articles of incorporation or bylaws?

The filing states that amendments to the articles of incorporation or bylaws were made, but the specific nature of these amendments is not detailed in the provided text.

What matters were submitted to a vote of security holders?

The report confirms that matters were submitted to a vote of security holders, but the specific proposals or resolutions are not outlined in the summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 22, 2025.

Where are Castle Biosciences' principal executive offices located?

Castle Biosciences, Inc.'s principal executive offices are located at 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546.

From the Filing

0001447362-25-000085.txt : 20250523 0001447362-25-000085.hdr.sgml : 20250523 20250523163901 ACCESSION NUMBER: 0001447362-25-000085 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250522 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 25983026 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 8-K 1 cstl-20250522.htm 8-K cstl-20250522 0001447362 FALSE 12/31 0001447362 2025-05-22 2025-05-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter)            Delaware   001-38984   77-0701774 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 505 S. Friendswood Drive , Suite 401 Friendswood , Texas 77546 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 866 ) 788-9007 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))    Securities registered pursuant to Section 12(b) of the Act:  Title of each class Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value per share CSTL   The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 3.03. Material Modifications of Rights of Security Holders. The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On May 22, 2025, Castle Biosciences, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meetin

View on Read The Filing